Table 2 Baseline characteristics of patients with rheumatoid arthritis included in the study
From: Effectiveness and safety of tofacitinib in rheumatoid arthritis: a cohort study
Variable | All patients (n = 21,832) | DMARDs (n = 5399) | TNFi ± DMARDs (n = 13,367) | Non-TNF biologics ± DMARDs (n = 2902) | Tofacitinib ± DMARDs (n = 164) |
|---|---|---|---|---|---|
Female sex, % | 77.0 | 76.8 | 76.1 | 81.4 | 78.7 |
Age, years, median (IQR) | 56 (48–63) | 57 (49–63) | 56 (48–63) | 58 (50–65) | 58 (50–64) |
Year of cohort entry, % | |||||
2011 | 48.5 | 25.9 | 52.3 | 70.5 | 0 |
2012 | 21.6 | 27.2 | 20.5 | 14.1 | 0.6 |
2013 | 14.7 | 21.9 | 13.1 | 8.7 | 43.9 |
2014 | 15.2 | 25.0 | 14.1 | 6.7 | 55.5 |
Urban residency, % | 82.6 | 81.1 | 83.2 | 82.8 | 89.4 |
Oral glucocorticoid use, % | |||||
No use | 32.3 | 29.2 | 33.4 | 33.0 | 31.0 |
≤ 7.5 mg/day of prednisone equivalent dose | 63.0 | 65.1 | 62.2 | 62.2 | 64.9 |
> 7.5 mg/day of prednisone equivalent dose | 4.7 | 5.7 | 4.4 | 4.8 | 4.0 |
Nonsteroidal anti-inflammatory drug use, % | 60.7 | 60.3 | 62.1 | 54.9 | 51.8 |
Selective COX-2 inhibitor use, % | 12.8 | 10.9 | 12.9 | 16.0 | 13.4 |
Charlson comorbidity index, mean (SD) | 0.61 (0.93) | 0.73 (1.04) | 0.54 (0.84) | 0.73 (1.02) | 0.86 (1.14) |
Infection-related hospitalization, % | 1.6 | 1.9 | 1.3 | 2.6 | 1.8 |
Number of emergency department visits, mean (SD) | 0.44 (1.20) | 0.48 (1.39) | 0.42 (1.14) | 0.44 (1.05) | 0.43 (0.83) |
Number of physician visits, mean (SD) | 17.99 (13.26) | 17.32 (14.07) | 17.37 (12.24) | 22.21 (15.24) | 16.70 (14.24) |
Number of rheumatology visits, mean (SD) | 4.51 (4.92) | 3.39 (3.85) | 4.54 (4.71) | 6.47 (6.75) | 3.88 (3.26) |
Number of hospitalizations, mean (SD) | 0.16 (0.50) | 0.16 (0.54) | 0.14 (0.45) | 0.23 (0.62) | 0.17 (0.62) |